Abstract
Migraine is a primary headache disorder and causes substantial pain and disability. Migraine sufferers could suffer from episodic migraine or chronic migraine. While both of these adversely affect the quality of life, the management of chronic migraine patients poses many challenges, as it mainly relies on preventive treatment. Till now, we have very limited options for preventive management of chronic migraine; recently, new drug erenumab has been approved by the Food and Drug Administration. It has shown very promising results in the management of chronic migraine as it acts by novel mechanism as calcitonin gene-related peptide receptor blocker.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
